초록 ▼

1. 인체시험
- 사이코스 복용 12주 후 DEXA로 측정한 체지방률 변화량이 세 군간 통계적으로 유의한 차이를 보임.

- 기저시점 대비 12주 시점의 허리둘레 변화량 또한 세 군간 통계적으로 유의한 차이를 보임.

- 이는 사이코스의 내장지방을 감소 및 복부비만을 개선하는 효과를 시사하는 것임.

- 간 CT, Alkaline phosphatase , y-GTP, ALT 등의 혈액검사 결과와 종합하면 비만으로 인한 비알콜성지방간염의 진행을 억제하는 사이코스의 효과를 기대할 수 있음.
<

1. 인체시험
- 사이코스 복용 12주 후 DEXA로 측정한 체지방률 변화량이 세 군간 통계적으로 유의한 차이를 보임.

- 기저시점 대비 12주 시점의 허리둘레 변화량 또한 세 군간 통계적으로 유의한 차이를 보임.

- 이는 사이코스의 내장지방을 감소 및 복부비만을 개선하는 효과를 시사하는 것임.

- 간 CT, Alkaline phosphatase , y-GTP, ALT 등의 혈액검사 결과와 종합하면 비만으로 인한 비알콜성지방간염의 진행을 억제하는 사이코스의 효과를 기대할 수 있음.

2. 동물실험
- ob/ob 마우스를 통한 사이코스의 체지방 축적억제 기작 증명

- 정상 체중을 가진 실험동물에서 포도당 섭취 후의 혈당 상승 정도를 감소 및 체중 및 체지방 무게의 감소를 유도를 증명. 지방 분해와 관련된 지표가 증가로 인한 체지방 죽적 억제효과 및 당 대사 조절 기능 개선 효과 증명

- 정상 체중 실험동물에서 고과당식이를 공급한 연구에서 사이코스의 지방조직 축적 억제 효과는 지방산화 활성화에 기인하는 것으로 세부기작 증명

3. 알룰로스 제품화
- 건강기능식 :구미제형 1종
- 체중조절식품 :시리얼바 1종
- 제과제빵용 식품 : 쿠키 2종
- 음료 : 일반음료, 커피 1종, 발효유 3종
- 크림 및 유지류 2종

(출처 : 요약서 3p)

Abstract ▼

Purpose & Contents
• The overall objective of this study was to verify the anti-obesity activity of D-psicose and elucidate the underlying mechanisms of action of D-psicose.

- D-Psicose is one of the monosaccharide sugar, which has 70% of the sweet taste of sucrose but almost zero calories

Purpose & Contents
• The overall objective of this study was to verify the anti-obesity activity of D-psicose and elucidate the underlying mechanisms of action of D-psicose.

- D-Psicose is one of the monosaccharide sugar, which has 70% of the sweet taste of sucrose but almost zero calories. Although some studies have reported a weight loss in animal models, the changes in body composition and hepatic steatosis beyond weight loss remain unexplored.

- We conducted a randomized, controlled study to examine the effect of D-psicose on visceral and hepatic fat in obesity.

- We performed a 12-wk randomized, placebo-controlled, double-blind, parallel group trial. Subjects were randomly assigned to receive placebo, lowdose D-psicose (6g/day), and high dose D-psicose (12g/day) on a 1:1:1 ratio. Anthropometric measurements, laboratory investigations, dual-energy x-ray absorptiometry (DEXA) and abdominal CTscan were performed at randomization (baseline) and at wk 12. Liver attenuation value, liver to spleen attenuation difference and liver-to-spleen attenuation ratio were measured as a measure of hepatic fat.

- We evaluated serumglucose concentrations and excess body fat deposition in response to D-psicose b o th in ob/ob and wild-type mice. We also investigated the effect of D-psicoes substitution for high-fructose diet on anti-obesity activity and its related mechanisms.

• Prototype
- functional food, weight control food, baked products, beverage, modified fat and fat based cream.

Results
• Human study
Baseline demographic, anthropometric, and clinical characteristics were similar among the groups. There was no significant difference in body weight and BMI among the groups. However, the D-psicose group showed significantly less increase of body fat mass frombaseline than in placebo group (P = 0.035). Although overall changes in lean body mass were not significantly different among the groups (P = 0.088), the reduction in waist circumference and visceral adipose tissue at week 12 was significant compared with placebofor all doses of D-psicose (-12.25±17.58 ㎠ in 12g D-psicose, and -6.27± 11.02 ㎠ in 6g D-psicose, p=0.001). Consistent with the decreased visceral fat, D-psicose treatment showed increased liver attenuation value, liver to spleen attenuation difference and liver-to-spleen attenuation ratio, which is indicative of an improvement in hepatic steatosis. D-psicose treatment was also associated with improvements in serumlevels of alanine aminotranferase (p=0.001) and glutamic pyruvic transaminase (p=0.042).

• Animal study
In ob/ob mice, 5% D-psicose supplementation decreased body weight, fat mass, lipid droplet size, and the expression of adipocyte differentiation-related markers, suggesting that it posseses the anti-obesity effect. In addition, the transcriptomic analysis showed that Fos, Mmp3, Fgf21, and Abcd2 might be key target genes associated with D-psicose-induced changes in lipid metabolismand further chronic inflammatory responses in adipose tissue of ob/ob mice. In wild-type mice, 5% D-psicose substitution for sucrose also decreased oral glucose tolerance, body weight gain and fat mass, while it increased the expression of lipolysis-related markers in adipose tissue.

These results indicate that D-psicose prevents excess fat deposition and improves glucose homeostasis.

Furthermore, 15% D-psicose + 15% fructose group lowered oral glucose tolerance, body weight gain, fat mass, and lipid droplet size compared to 30% high-fructose group, whereas it increased the expression of lipolysis-related genes compared to the control group. The levels of lipogenesis-related genes was increased compared to control group, but there were no significant differences between D-psicose and high-fructose group except PPARy. Taken together, our data suggest that D-psicose-induced anti-obesity effect would be associated with the activation of lipolysis and 3 -oxidation.

• Prototype
- functional food : G umi shape 1type
- weight control food : serial bar 1type
- baked products : cookie 1 types, chocolate 1 types, brownie 1 type
- beverage : carbonate beverage 1 types, coffee 1 type, yogurt 3types
- modified fat and fat based cream2 type

Expected Contribution
To our knowledge, the present study is the first to demonstrate the effect of D-psicose on body composition and hepatic steatosis in obesity. We found a significantly decreased abdominal visceral fat, and not fat-free body mass, including muscle. Furthermore, D-allulose improved hepatic steatosis. D-Psicose may be useful as a supplement for preventing and improving obesity and obesity-related disorders.

We observe anti-obesity effect in mouse related to obesity and supply baseline data that investigate its role, and these can be competitive research material in related fields. Through verifying related psicose's effectiveness by animal experiment, we produced results that can be applied in the industrial world. Especially, we investigate relationship between human gut microbime and colitis providing information that involves high research interest. Identification of gut microbial profile and inflammatory marker difference between patient and normal controls, can be utilized as useful information for later intervention study.

(출처 : SUMMARY 8p)

목차 Contents

• 표지 ... 1
• 제 출 문 ... 2
• 보고서 요약서 ... 3
• 요약문 ... 5
• SUMMARY ... 8
• CONTENTS ... 10
• 목차 ... 11
• 1장. 연구개발과제의 개요 ... 12
• 1절. 연구개발 목적 ... 12
• 2절. 연구개발의 필요성 ... 12
• 3절. 연구개발 범위 ... 17
• 2장. 국내외 기술개발 현황 ... 18
• 1절. 사이코스 (D-psicose)의 항비만 효능 ... 18
• 2절. 사이코스 (D-psicose)의 안전성 평가 ... 19
• 3장. 연구수행 내용 및 결과 ... 21
• 1절. 인체시험 ... 21
• 2절. 동물시험 ... 31
• 3절 사이코스 제품화 ... 62
• 4장. 목표달성도 및 관련분야 기여도 ... 119
• 1절. 임상실험 목표달성도 100% ... 119
• 2절. 동물실험 목표달성도 100% ... 120
• 3절. 사이코스 제품화 목표달성도 90% ... 120
• 4절. 관련분야 기여도 ... 122
• 5장. 연구결과의 활용계획 ... 123
• 6장. 연구과정에서 수집한 해외과학기술정보 ... 124
• 7장. 연구개발결과의 보안등급 ... 125
• 8장. 국가과학기술종합정보시스템에 등록한 연구시설·장비 현황 ... 125
• 9장. 연구개발과제 수행에 따른 연구실 등의 안전조치 이행실적 ... 125
• 10장. 연구개발과제의 대표적 연구실적 ... 154
• 11장. 기타사항 ... 182
• 12장. 참고문헌 ... 183
• 끝페이지 ... 184